4.8 Review

Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products

期刊

JOURNAL OF CONTROLLED RELEASE
卷 351, 期 -, 页码 215-230

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2022.09.031

关键词

Polyethylene glycol (PEG); anti -PEG antibodies; Hypersensitivity; COVID-19 mRNA vaccines; complement activation -related pseudoallergy; (CARPA)

资金

  1. Ministry of Higher Education of the Arab Republic of Egypt
  2. JSPS International Fellowships for Research in Japan
  3. JSPS Research Fellow [20F20411]
  4. Fostering Joint International Research [19KK0279]
  5. Japan Society for the Promotion of Science [21H05526]
  6. Egyptian Government represented in the Cultural Affairs and Missions Sectors (Ministry of High Education)
  7. Nagai Foundation Tokyo
  8. KOS'E Cosmetology Research Foundation
  9. Tokushima University

向作者/读者索取更多资源

Polyethylene glycol (PEG) is widely used as an additive in foods and cosmetics, and as a carrier in PEGylated therapeutics. However, there is mounting evidence that PEG causes immunogenic responses when conjugated with other materials, resulting in the production of anti-PEG antibodies. These antibodies can negatively impact the therapeutic efficacy of PEGylated formulations and hypersensitivity reactions to PEGylated products can be a significant barrier to their utility.
Polyethylene glycol (PEG) is a versatile polymer that is widely used as an additive in foods and cosmetics, and as a carrier in PEGylated therapeutics. Even though PEG is thought to be less immunogenic, or perhaps even non -immunogenic, with a variety of physicochemical properties, there is mounting evidence that PEG causes immunogenic responses when conjugated with other materials such as proteins and nanocarriers. Under these conditions, PEG with other materials can result in the production of anti-PEG antibodies after administration. The antibodies that are induced seem to have a deleterious impact on the therapeutic efficacy of subsequently administered PEGylated formulations. In addition, hypersensitivity to PEGylated formulations could be a sig-nificant barrier to the utility of PEGylated products. Several reports have linked the presence of anti-PEG anti-bodies to incidences of complement activation-related pseudoallergy (CARPA) following the administration of PEGylated formulations. The use of COVID-19 mRNA vaccines, which are composed mainly of PEGylated lipid nanoparticles (LNPs), has recently gained wide acceptance, although many cases of post-vaccination hyper-sensitivity have been documented. Therefore, our review focuses not only on the importance of PEGs and its great role in improving the therapeutic efficacy of various medications, but also on the hypersensitivity reactions attributed to the use of PEGylated products that include PEG-based mRNA COVID-19 vaccines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据